Iqvia price target lowered to $210 from $225 at Citi

Citi analyst Patrick Donnelly lowered the firm’s price target on Iqvia (IQV) to $210 from $225 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post the Q4 reports. Coming away from earnings, investor appetite for the sector “remains very light,” primarily due to ongoing U.S. government pressure, the analyst tells investors in a research note. However, Citi sees pockets of the market to be constructive on, such as bioprocessing, where it believes a recovery is underway. Danaher (DHR) is the firm’s top pick.